Clinical trials: Urogenital Cancers
Ovarian Neoplasms
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart.
- Trial name
- NCT00034372
- Testing
- oregovomab
- Where
- 17 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Unither Pharmaceuticals
Ovarian Cancer
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma…
- Trial name
- NCT01422265
- Where
- 31 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Urothelial Carcinoma
Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma
Urothelial carcinoma (UC) is the most common malignancy of the urinary system. Hematuria is a significant clinical manifestation of UC, often diagnosed through invasive procedures.
- Trial name
- UMT-UC (NCT06912672)
- Testing
- Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer
- Volunteers
- 1,500 people
- Sponsor
- Shanghai Epiprobe Biotechnology Co., Ltd.
Prostate Cancer
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer
- Trial name
- NCT03199872
- Testing
- RV001V
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- RhoVac APS
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
- Trial name
- NCT01114230
- Testing
- AGS-16M8F
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer, Prostate Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer
- Trial name
- NeoFIND (NCT03724253)
- Testing
- [68Ga]-NeoBOMB1
- Where
- 3 sites in Austria, France
- Volunteers
- 19 people
- Sponsor
- Advanced Accelerator Applications
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Peritoneal Metastases
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
The objective of this feasibility study is to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and…
- Trial name
- NCT03834272
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lumicell, Inc.
Solid Tumor, Advanced Solid Tumor
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
- Trial name
- NCT06586957
- Testing
- NKT3964, Paclitaxel, Doxorubicin
- Where
- 21 sites in United States, South Korea
- Volunteers
- 238 people
- Sponsor
- NiKang Therapeutics, Inc.
Prostate Cancer
Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations for Radiation Oncologists
This clinical utility study is based on a review of real but de-identified and randomized patient cases and aims to evaluate radiation oncologist's treatment recommendations before and after reviewing the results provided by the…
- Trial name
- DECIDE3 (NCT02034812)
- Testing
- Decipher Questionnaire
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GenomeDx Biosciences Corp
Tumor
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
- Trial name
- CheckMate 76U (NCT04311710)
- Testing
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Cancer of the Prostate
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
The objective of this clinical study is to evaluate the safety and efficacy of three different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the maintenance of testosterone (T) suppression in men with…
- Trial name
- MASTERS (NCT02349386)
- Testing
- BHR-200 (0.36% transdermal 17β-estradiol gel)
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- BHR Pharma, LLC
Prostate Cancer
Focal Prostate Radiofrequency Ablation
To assess the early histological outcomes of tissue ablation, adverse events and genitourinary side-effect profile of focal radiofrequency ablation using a coiled bipolar device to treat localized prostate cancer in men with…
- Trial name
- ProRAFT (NCT02294903)
- Testing
- Coiled Bipolar Radiofrequency Ablation
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Trod Medical N.V.
Prostatic Neoplasms
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP)…
- Trial name
- NCT05295927
- Testing
- EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone
- Where
- 4 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
- Trial name
- ARX517 (NCT04662580)
- Testing
- ARX517, Apalutamide, Abiraterone acetate
- Where
- 12 sites in United States
- Volunteers
- 183 people
- Sponsor
- Janssen Research & Development, LLC
Liver Metastases, Liver Metastasis Colon Cancer
DNX-2440 for Resectable Colorectal Liver Metastasis
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery.
- Conditions
- Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04714983
- Testing
- DNX-2440
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- DNAtrix, Inc.
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Prostatic Neoplasm
Treatment Patterns in Metastatic Prostate Cancer
This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives).
- Trial name
- NCT02729103
- Testing
- Xofigo (Radium 223 dichloride,BAY88-8223)
- Where
- United States
- Volunteers
- 565 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.